[
  {
    "ts": null,
    "headline": "Stock Market Today: Dow Wobbles As Nvidia Slides; Google Jumps On Warren Buffett Stake (Live Coverage)",
    "summary": "Stock Market Today: The Dow Jones index wavered Monday as Nvidia declined in premarket trading. Google stock jumped on a Warren Buffett purchase.",
    "url": "https://finnhub.io/api/news?id=205de5bbb3569454dbd62879bd5b41c3b4960cce15a4ba922ad093ae079b6ac4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763384468,
      "headline": "Stock Market Today: Dow Wobbles As Nvidia Slides; Google Jumps On Warren Buffett Stake (Live Coverage)",
      "id": 137503938,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Stock Market Today: The Dow Jones index wavered Monday as Nvidia declined in premarket trading. Google stock jumped on a Warren Buffett purchase.",
      "url": "https://finnhub.io/api/news?id=205de5bbb3569454dbd62879bd5b41c3b4960cce15a4ba922ad093ae079b6ac4"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Softer Late Afternoon",
    "summary": "Health care stocks were decreasing late Monday afternoon with the NYSE Health Care Index and the Hea",
    "url": "https://finnhub.io/api/news?id=b522a1078a77b6a152d26dc3ba99a95cf3e289fc3e784e72f6f7c4b7423d6929",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763413077,
      "headline": "Sector Update: Health Care Stocks Softer Late Afternoon",
      "id": 137522814,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Health care stocks were decreasing late Monday afternoon with the NYSE Health Care Index and the Hea",
      "url": "https://finnhub.io/api/news?id=b522a1078a77b6a152d26dc3ba99a95cf3e289fc3e784e72f6f7c4b7423d6929"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Will Buy Cancer Drugmaker Halda Therapeutics for $3.1 Billion",
    "summary": "Halda is testing a prostate cancer drug. J&J says that with the acquisition it will gain a platform for treating “diseases beyond oncology.”",
    "url": "https://finnhub.io/api/news?id=88de1d185474d9a657b01837408a5d192f7386238fe7090eeb8aa1a99bc1059e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763403600,
      "headline": "Johnson & Johnson Will Buy Cancer Drugmaker Halda Therapeutics for $3.1 Billion",
      "id": 137506320,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Halda is testing a prostate cancer drug. J&J says that with the acquisition it will gain a platform for treating “diseases beyond oncology.”",
      "url": "https://finnhub.io/api/news?id=88de1d185474d9a657b01837408a5d192f7386238fe7090eeb8aa1a99bc1059e"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Inks A $3.05 Billion Deal In Cancer Treatment",
    "summary": "Johnson & Johnson said Monday it's putting up $3.05 billion to buy privately held cancer player Halda Therapeutics.",
    "url": "https://finnhub.io/api/news?id=6dea7c67797e550ae7f14b427d99e2f00f1bb7467b5e137ee96962968e239e97",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763401457,
      "headline": "Johnson & Johnson Inks A $3.05 Billion Deal In Cancer Treatment",
      "id": 137506321,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson said Monday it's putting up $3.05 billion to buy privately held cancer player Halda Therapeutics.",
      "url": "https://finnhub.io/api/news?id=6dea7c67797e550ae7f14b427d99e2f00f1bb7467b5e137ee96962968e239e97"
    }
  },
  {
    "ts": null,
    "headline": "Top Midday Stories: Amazon to Sell Used Ford Vehicles on Website; Novo Nordisk Cuts Wegovy, Ozempic Prices",
    "summary": "The Dow Jones Industrial Average was down, the Nasdaq Composite was higher, and the S&P 500 was roug",
    "url": "https://finnhub.io/api/news?id=5e701494e516467f1d7df91746887b41c573c66665b7b214556cb37a997d0f16",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763397852,
      "headline": "Top Midday Stories: Amazon to Sell Used Ford Vehicles on Website; Novo Nordisk Cuts Wegovy, Ozempic Prices",
      "id": 137506135,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The Dow Jones Industrial Average was down, the Nasdaq Composite was higher, and the S&P 500 was roug",
      "url": "https://finnhub.io/api/news?id=5e701494e516467f1d7df91746887b41c573c66665b7b214556cb37a997d0f16"
    }
  },
  {
    "ts": null,
    "headline": "Correction: Johnson & Johnson Strikes $3.05 Billion Deal to Buy Cancer Drug Developer Halda",
    "summary": "(Corrected to add \"billion\" in headline.) Johnson & Johnson (JNJ) has agreed to buy Halda Therape",
    "url": "https://finnhub.io/api/news?id=821d792cdcf617fc7c94e64d037b5bae47961b742a1d1ba32482809ea1d364f3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763396706,
      "headline": "Correction: Johnson & Johnson Strikes $3.05 Billion Deal to Buy Cancer Drug Developer Halda",
      "id": 137506323,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "(Corrected to add \"billion\" in headline.) Johnson & Johnson (JNJ) has agreed to buy Halda Therape",
      "url": "https://finnhub.io/api/news?id=821d792cdcf617fc7c94e64d037b5bae47961b742a1d1ba32482809ea1d364f3"
    }
  },
  {
    "ts": null,
    "headline": "J&J to acquire Halda, Sinclair takes 8.2% stake in E.W. Scripps",
    "summary": "Market Catalysts host Julie Hyman tracks several of the day's top trending stock tickers, including Johnson & Johnson's (JNJ) move to broaden its cancer research portfolio by acquiring Halda Therapeutics for $3 billion, Sinclair Broadcast Group (SBGI) taking a stake in broadcasting company E.W. Scripps (SSP), and bubble-wrap inventor Sealed Air (SEE) agreeing to go private in a deal with private equity firm CD&R. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.",
    "url": "https://finnhub.io/api/news?id=ef2d26561028d66c0e6ffe0d3bce0b2b8564c99ee3de509318250a99cba4bf7b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763394196,
      "headline": "J&J to acquire Halda, Sinclair takes 8.2% stake in E.W. Scripps",
      "id": 137506324,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Market Catalysts host Julie Hyman tracks several of the day's top trending stock tickers, including Johnson & Johnson's (JNJ) move to broaden its cancer research portfolio by acquiring Halda Therapeutics for $3 billion, Sinclair Broadcast Group (SBGI) taking a stake in broadcasting company E.W. Scripps (SSP), and bubble-wrap inventor Sealed Air (SEE) agreeing to go private in a deal with private equity firm CD&R. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.",
      "url": "https://finnhub.io/api/news?id=ef2d26561028d66c0e6ffe0d3bce0b2b8564c99ee3de509318250a99cba4bf7b"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Strikes $3.05 Deal to Buy Cancer Drug Developer Halda",
    "summary": "Johnson & Johnson (JNJ) has agreed to buy Halda Therapeutics for $3.05 billion in cash as the health",
    "url": "https://finnhub.io/api/news?id=3fb683fdc42dc4f4a66fdff7f1dc0d412aaba30ae8cfccae10a250f5b447a08a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763393863,
      "headline": "Johnson & Johnson Strikes $3.05 Deal to Buy Cancer Drug Developer Halda",
      "id": 137506325,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (JNJ) has agreed to buy Halda Therapeutics for $3.05 billion in cash as the health",
      "url": "https://finnhub.io/api/news?id=3fb683fdc42dc4f4a66fdff7f1dc0d412aaba30ae8cfccae10a250f5b447a08a"
    }
  },
  {
    "ts": null,
    "headline": "BMY Stock Down on Discontinuation of ACS Clinical Study With JNJ",
    "summary": "BMY shares drop after halting the Librexia ACS trial, though other milvexian studies continue with top-line data expected in 2026.",
    "url": "https://finnhub.io/api/news?id=1d3afe7014a8ddbe4402b8b86b25f8dcb76629e0a35084eab1c9e33c8861acd0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763387880,
      "headline": "BMY Stock Down on Discontinuation of ACS Clinical Study With JNJ",
      "id": 137506326,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "BMY shares drop after halting the Librexia ACS trial, though other milvexian studies continue with top-line data expected in 2026.",
      "url": "https://finnhub.io/api/news?id=1d3afe7014a8ddbe4402b8b86b25f8dcb76629e0a35084eab1c9e33c8861acd0"
    }
  },
  {
    "ts": null,
    "headline": "Take the Zacks Approach to Beat the Markets: Macy's, United Natural Foods & Monster Beverage in Focus",
    "summary": "Macy's climbs after a Zacks upgrade as multiple portfolios showcase strong gains across UNFI, Monster Beverage and other standout stocks.",
    "url": "https://finnhub.io/api/news?id=5855f23f13311b10294a5754b03a8b23d5ceb14ef1e8f429c47f03fa17e7c212",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763386800,
      "headline": "Take the Zacks Approach to Beat the Markets: Macy's, United Natural Foods & Monster Beverage in Focus",
      "id": 137506327,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Macy's climbs after a Zacks upgrade as multiple portfolios showcase strong gains across UNFI, Monster Beverage and other standout stocks.",
      "url": "https://finnhub.io/api/news?id=5855f23f13311b10294a5754b03a8b23d5ceb14ef1e8f429c47f03fa17e7c212"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson to Buy Halda Therapeutics For $3.05 Billion",
    "summary": "Johnson & Johnson has agreed to buy clinical-stage biotechnology company Halda Therapeutics for $3.05 billion in cash in a deal that bolsters the healthcare giant’s oncology pipeline.",
    "url": "https://finnhub.io/api/news?id=ec1244a601b92b83e9b70b30000966d3f938f2cb125e20108717e1fac33115cf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763386140,
      "headline": "Johnson & Johnson to Buy Halda Therapeutics For $3.05 Billion",
      "id": 137506328,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson has agreed to buy clinical-stage biotechnology company Halda Therapeutics for $3.05 billion in cash in a deal that bolsters the healthcare giant’s oncology pipeline.",
      "url": "https://finnhub.io/api/news?id=ec1244a601b92b83e9b70b30000966d3f938f2cb125e20108717e1fac33115cf"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript",
    "summary": "Johnson & Johnson (JNJ) 7th Annual Wolfe Research Healthcare Conference November 17, 2025 10:40 AM ESTCompany ParticipantsCandice Long - Worldwide Vice...",
    "url": "https://finnhub.io/api/news?id=a7bce3fecae989da16cdba33107b3f3efe7188db691c062daf35789776ee244e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763385428,
      "headline": "Johnson & Johnson (JNJ) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript",
      "id": 137505828,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Johnson & Johnson (JNJ) 7th Annual Wolfe Research Healthcare Conference November 17, 2025 10:40 AM ESTCompany ParticipantsCandice Long - Worldwide Vice...",
      "url": "https://finnhub.io/api/news?id=a7bce3fecae989da16cdba33107b3f3efe7188db691c062daf35789776ee244e"
    }
  },
  {
    "ts": null,
    "headline": "Halda Therapeutics Announces Acquisition by Johnson & Johnson",
    "summary": "Halda to be acquired by Johnson & Johnson for $3.05 billion in cashHalda recently presented positive Phase 1/2 data for HLD-0915 in metastatic castration-resistant prostate cancer and continues rapid clinical developmentAdditional RIPTAC™ programs in development for major solid tumor types and other serious diseases NEW HAVEN, Conn., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Halda Therapeutics announced today that it has entered into a definitive agreement pursuant to which Johnson & Johnson will acquir",
    "url": "https://finnhub.io/api/news?id=a2fa5fc2b5a776be689cc9f330c1b46f85af54a868feee562bfb357e70e69866",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763385300,
      "headline": "Halda Therapeutics Announces Acquisition by Johnson & Johnson",
      "id": 137506329,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Halda to be acquired by Johnson & Johnson for $3.05 billion in cashHalda recently presented positive Phase 1/2 data for HLD-0915 in metastatic castration-resistant prostate cancer and continues rapid clinical developmentAdditional RIPTAC™ programs in development for major solid tumor types and other serious diseases NEW HAVEN, Conn., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Halda Therapeutics announced today that it has entered into a definitive agreement pursuant to which Johnson & Johnson will acquir",
      "url": "https://finnhub.io/api/news?id=a2fa5fc2b5a776be689cc9f330c1b46f85af54a868feee562bfb357e70e69866"
    }
  },
  {
    "ts": null,
    "headline": "New long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis",
    "summary": "Johnson & Johnson (NYSE: JNJ) today announced new data from the Phase 3b APEX study showing that TREMFYA® continued to reduce both signs and symptoms of active psoriatic arthritis (PsA) and inhibit progression of structural damage at 48 weeks.1 These data were presented at the Inflammatory Skin Disease Summit (ISDS) 2025.",
    "url": "https://finnhub.io/api/news?id=4938196bd5ed794a50e6b02a05b8d3a0111b08b5c3b656cedbdfe44f38febbcb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763384700,
      "headline": "New long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis",
      "id": 137504072,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE: JNJ) today announced new data from the Phase 3b APEX study showing that TREMFYA® continued to reduce both signs and symptoms of active psoriatic arthritis (PsA) and inhibit progression of structural damage at 48 weeks.1 These data were presented at the Inflammatory Skin Disease Summit (ISDS) 2025.",
      "url": "https://finnhub.io/api/news?id=4938196bd5ed794a50e6b02a05b8d3a0111b08b5c3b656cedbdfe44f38febbcb"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Set to Revolutionize the Treatment of Cancer With the Acquisition of Halda Therapeutics",
    "summary": "NEW BRUNSWICK, N.J., November 17, 2025--Johnson & Johnson (NYSE: JNJ) announced today that it has entered into a definitive agreement to acquire Halda Therapeutics OpCo, Inc. (Halda), a clinical-stage biotechnology company with a proprietary Regulated Induced Proximity TArgeting Chimera (RIPTAC™) platform to develop oral, targeted therapies for multiple types of solid tumors, including prostate cancer, for $3.05 billion in cash. The transaction is expected to close within the next few months, su",
    "url": "https://finnhub.io/api/news?id=f10858d93c726f1ebd7fdadc82f63306d7116c4386193dfaf86a4fe66ec838e5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763384400,
      "headline": "Johnson & Johnson Set to Revolutionize the Treatment of Cancer With the Acquisition of Halda Therapeutics",
      "id": 137506330,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "NEW BRUNSWICK, N.J., November 17, 2025--Johnson & Johnson (NYSE: JNJ) announced today that it has entered into a definitive agreement to acquire Halda Therapeutics OpCo, Inc. (Halda), a clinical-stage biotechnology company with a proprietary Regulated Induced Proximity TArgeting Chimera (RIPTAC™) platform to develop oral, targeted therapies for multiple types of solid tumors, including prostate cancer, for $3.05 billion in cash. The transaction is expected to close within the next few months, su",
      "url": "https://finnhub.io/api/news?id=f10858d93c726f1ebd7fdadc82f63306d7116c4386193dfaf86a4fe66ec838e5"
    }
  },
  {
    "ts": null,
    "headline": "J&J adds to pharma’s M&A spree with $3B buyout of startup Halda",
    "summary": "The deal gives J&J access to a pipeline of drugs designed to “hold and kill” tumors, led by a prostate cancer medicine that’s shown promise in early-stage testing.",
    "url": "https://finnhub.io/api/news?id=6d81d58f60832402d3772d1f319374e87b9adb12a79314dbcb413f64bf2d674c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763381280,
      "headline": "J&J adds to pharma’s M&A spree with $3B buyout of startup Halda",
      "id": 137506332,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The deal gives J&J access to a pipeline of drugs designed to “hold and kill” tumors, led by a prostate cancer medicine that’s shown promise in early-stage testing.",
      "url": "https://finnhub.io/api/news?id=6d81d58f60832402d3772d1f319374e87b9adb12a79314dbcb413f64bf2d674c"
    }
  },
  {
    "ts": null,
    "headline": "Growth or Stability? A 2025 Investment Face-Off Between LLY and JNJ",
    "summary": "Eli Lilly's surging GLP-1 momentum and Johnson & Johnson's diversified strength set up a compelling 2025 showdown for investors weighing growth vs. stability.",
    "url": "https://finnhub.io/api/news?id=dfd0d4641251f6cdcaa53f6124ac74da2fef75d0661da8b8b3872640a1ed46be",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763381280,
      "headline": "Growth or Stability? A 2025 Investment Face-Off Between LLY and JNJ",
      "id": 137506305,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Eli Lilly's surging GLP-1 momentum and Johnson & Johnson's diversified strength set up a compelling 2025 showdown for investors weighing growth vs. stability.",
      "url": "https://finnhub.io/api/news?id=dfd0d4641251f6cdcaa53f6124ac74da2fef75d0661da8b8b3872640a1ed46be"
    }
  },
  {
    "ts": null,
    "headline": "The Club's top 10 things to watch in the stock market Monday",
    "summary": "Stock futures are relatively muted early this morning. The market is coming off a volatile week, driven by doubts about the sustainability of AI spending.",
    "url": "https://finnhub.io/api/news?id=ec2712827bd069539f87cf6a3ae1272d68a0677dae42cd005b604ef60c644c6d",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763370143,
      "headline": "The Club's top 10 things to watch in the stock market Monday",
      "id": 137505318,
      "image": "https://image.cnbcfm.com/api/v1/image/108196778-1757507590799-gettyimages-2234563479-_73a3022_jnkqswz6.jpeg?v=1763386323&w=1920&h=1080",
      "related": "JNJ",
      "source": "CNBC",
      "summary": "Stock futures are relatively muted early this morning. The market is coming off a volatile week, driven by doubts about the sustainability of AI spending.",
      "url": "https://finnhub.io/api/news?id=ec2712827bd069539f87cf6a3ae1272d68a0677dae42cd005b604ef60c644c6d"
    }
  }
]